Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients

Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients

Abstract Background Up to 23% of breast cancer patients recurred within a decade after trastuzumab treatment. Conversely, one trial found that patients with low HER2 expression and metastatic breast cancer had a positive response to trastuzumab-deruxtecan (T-Dxd). This indicates that relying solely...

Full description

Saved in:
Bibliographic Details
Main Authors: Tzu-Chun Cheng, Mien-Chie Hung, Lu-Hai Wang, Shih-Hsin Tu, Chih-Hsiung Wu, Yun Yen, Chi-Long Chen, Jacqueline Whang-Peng, Wen-Jui Lee, You-Cheng Liao, Yu-Ching Lee, Min-Hsiung Pan, Hui-Kuan Lin, Huey-En Tzeng, Peixuan Guo, Cheng-Ying Chu, Li-Ching Chen, Yuan-Soon Ho
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Biomarker Research
Subjects:
Anti-HER2 therapy responder
Breast cancer
Histamine N-methyltransferase
H-cell phenotype
Nuclear translocation
Online Access:https://doi.org/10.1186/s40364-024-00715-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40364-024-00715-5

Similar Items